Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | PHGDH | O43175 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13417642 | 1.00 | POLB (0.53) | POLBHSD17B10SIGMAR1HRH3PHGDH | |
| SCHEMBL13137477 | 1.00 | POLB (0.53) | POLBHSD17B10SIGMAR1HRH3PHGDH | |
| SCHEMBL13417645 | 0.98 | POLB (0.50) | POLBHSD17B10SIGMAR1HRH3PHGDH | |
| SCHEMBL4546623 | 0.94 | POLB (0.46) | POLBHSD17B10SIGMAR1HRH3PHGDH | |
| SCHEMBL15504825 | 0.90 | MTNR1A (0.43) | POLBHSD17B10SIGMAR1HRH3KCNH2 | |
| SCHEMBL25107536 | 0.86 | MEN1 (0.46) | ALDH1A1KDM4EMEN1KMT2AL3MBTL3 | |
| SCHEMBL12396446 | 0.85 | CYP3A4 (0.55) | ALDH1A1KDM4EMEN1KMT2AL3MBTL3 | |
| SCHEMBL4546639 | 0.84 | TSHR (0.39) | POLBHSD17B10SIGMAR1HRH3GAA | |
| SCHEMBL12308328 | 0.84 | CHRM1 (0.53) | POLBSIGMAR1HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL18251701 | 0.83 | CYP3A4 (0.52) | L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130156788-A1 | FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 | OXFORD BIOTHERAPEUTICS LTD (GB) | 2013-06-20 | — | — | US | disclosed |
| US-8420084-B2 | Fully human antibodies specific to CADM1 | MEDAREX, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120093826-A1 | FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 | OXFORD BIOTHERAPEUTICS LTD (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20120027782-A1 | MONOCLONAL ANTIBODY PARTNER MOLECULE CONJUGATES DIRECTED TO PROTEIN TYROSINE KINASE 7 (PTK7) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
| US-20110085970-A1 | ANTI-B7H4 MONOCLONAL ANTIBODY-DRUG CONJUGATE AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-14 | — | — | US | disclosed |
| US-20110020329-A1 | CONJUGATES OF ANTI-RG-1 ANTIBODIES | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | disclosed |
| US-7807704-B2 | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 | CHEMOCENTRYX, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7671069-B2 | Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20090162372-A1 | FIBRONECTIN ED-B ANTIBODIES, CONJUGATES THEREOF, AND METHODS OF USE | MEDAREX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20070275965-A1 | CXCR4 modulators | CHEMOCENTRYX, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162372-A1 | FIBRONECTIN ED-B ANTIBODIES, CONJUGATES THEREOF, AND METHODS OF USE | FN1, EDNRB, EDF1 | POLB 3600/4885HSD17B10 4045/4885SIGMAR1 4257/4885 |
| US-20110085970-A1 | ANTI-B7H4 MONOCLONAL ANTIBODY-DRUG CONJUGATE AND METHODS OF USE | CD2BP2, CD274, CD22 | POLB 2133/4885HSD17B10 3632/4885SIGMAR1 2555/4885 |
| US-20120093826-A1 | FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 | FCGR1A, FCGR2A, FCGR3B | POLB 1443/4885HSD17B10 4531/4885SIGMAR1 4180/4885 |
| US-20070275965-A1 | CXCR4 modulators | CXCL12, CXCR4, CXCR1 | POLB 4479/4885HSD17B10 3413/4885SIGMAR1 2998/4885 |
| US-20130156788-A1 | FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 | FCGR1A, FCGR2A, FCGR3B | POLB 1443/4885HSD17B10 4531/4885SIGMAR1 4180/4885 |
| US-20110020329-A1 | CONJUGATES OF ANTI-RG-1 ANTIBODIES | GDI1, ARFGAP1, GLG1 | POLB 3724/4885HSD17B10 4456/4885SIGMAR1 2986/4885 |
| US-20120027782-A1 | MONOCLONAL ANTIBODY PARTNER MOLECULE CONJUGATES DIRECTED TO PROTEIN TYROSINE KINASE 7 (PTK7) | PTK2, PTK2B, LTK | POLB 3824/4885HSD17B10 3401/4885SIGMAR1 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.